Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

Blood - 23 Jan 2014

Laszlo George S, Gudgeon Chelsea J, Harrington Kimberly H, Dell'Aringa Justine, Newhall Kathryn J, Means Gary D, Sinclair Angus M, Kischel Roman, Frankel Stanley R, Walter Roland B

Abstract excerpt

CD33 is a valid target for acute myeloid leukemia (AML) but has proven challenging for antibody-drug conjugates. Herein, we investigated the cellular determinants for the activity of the novel CD33/CD3-directed bispecific T-cell engager antibody, AMG 330. In the presence of T cells, AMG 330 was highly active against human AML cell lines and primary AML cells in a dose- and effector to target cell ratio-dependent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AC133 Antigen
Share to Antibodies, Bispecific

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to CD3 Complex

Share to HL-60 Cells

Share to Hydroxamic Acids

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Sialic Acid Binding Ig-like Lectin 3

Source

Open in PubMed Open full text

Identifiers

PMID: 24311721
DOI: 10.1182/blood-2013-09-527044
PMCID: PMC3901068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.PMID 24311721Read ↗

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read ↗

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLSemantic proximity Read ↗

Development of a bispecific Antibody–Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid LeukaemiaSemantic proximity Read ↗

Targeting CD33 for acute myeloid leukemia therapy.Semantic proximity Read ↗

Targeting CD33 for Acute Myeloid Leukemia TherapySemantic proximity Read ↗

CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.Semantic proximity Read ↗

Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemiaSemantic proximity Read ↗

Gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublinesSemantic proximity Read ↗

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaSemantic proximity Read ↗

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugateSemantic proximity Read ↗

The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.